Lipitor Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Mounting Litigation Over Statin Medication’s Alleged Association With Type 2 Diabetes
New York, New York (PRWEB) February 21, 2015 -- Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) alleging the cholesterol-lowering statin is associated with an increased risk of new-onset Type 2 diabetes continue to mount in a federal multidistrict litigation now underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to an updated Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on February 17, 2015, 1,817 claims are now pending in the proceeding. Court filings indicate that this represents an increase of more than 200 filings since January 15th, when the Panel reported a total of 1,603 cases. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“According to court papers, this multidistrict litigation is just over a year old, as the JPML’s Initial Transfer Order establishing the proceeding was issued on February 19, 2014. At that time, just over 50 Lipitor lawsuits had been consolidated in the District of South Carolina,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. "Like all multidstrict litigations, this proceeding was established in the anticipation that hundreds of cases involving similar allegations could be filed. This latest update from the JPML indicates that those expectations are being borne out." Bernstein Liebhard LLP is currently representing Lipitor lawsuit plaintiffs in the federal proceeding, and continues to offer free and confidential case evaluations to individuals who allegedly developed Type 2 diabetes due to their use of Lipitor.
Lipitor Litigation History
Court documents indicate that the federal Lipitor litigation was established just two years after the U.S. Food & Drug Administration (FDA) announced that the labels for Lipitor and other statins would be updated to include new information about their potential effects on blood sugar levels. In its February 28, 2012 announcement, the agency indicated that the label change was prompted by a review that included, among other things, a study published the previous month in JAMA: Internal Medicine which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *
According to court documents, all of the Lipitor lawsuits currently pending in the multidistrict litigation underway in South Carolina federal court accuse Pfizer Inc. of concealing the association between Lipitor and diabetes in order to protect sales of the drug. Plaintiffs further allege that the label modifications made by Pfizer in 2012 still do not adequately address this risk, and assert that they would have never used the statin had they been aware of its association with diabetes.
Type 2 diabetes patients who allegedly developed the disease due to their use of Lipitor may be entitled to compensation from Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 23, 2012.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Lipitor Lawsuit Diabetes Information Center, http://www.lipitorlawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article